Please ensure Javascript is enabled for purposes of website accessibility

Here's Why BeiGene Ltd. Rose as Much as 31.4% on Thursday

By Maxx Chatsko - Jul 6, 2017 at 2:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The mid-cap Chinese biopharma announced a collaboration with Celgene that has a few interesting twists to it.

What happened

Shares of BeiGene Ltd. (BGNE 3.59%) rocketed more than 31% higher at one point Thursday morning after the clinical-stage biopharma announced a new collaboration with Celgene Corp. (CELG). The biopharma giant acquired worldwide rights outside of Asia to the upstart's PD-1 inhibitor BGB-A317, a pipeline drug candidate identified for immuno-oncology applications to treat solid tumors. 

In a bit of a twist as far as such collaborations go, BeiGene is acquiring something from Celgene as well. The $2.6 billion market-cap upstart is getting all Chinese commercial operations of the $103 billion company, and an exclusive license to sell Celgene's blockbuster drugs Abraxane, Revlimid, and Vidaza in China. As of 2:05 p.m. EDT, the stock had settled to a 26.3% rise. With those gains, BeiGene shares have more than doubled in 2017. 

A dude holding an arrow facing up.

Image source: Getty Images.

So what

BeiGene will receive an upfront payment of $263 million, in addition to a $150 million equity investment from Celgene, which will nearly double the company's cash position from the end of March. It will also retain commercial rights to BGB-A317 in Asia (excluding Japan).

What does all this mean? Well, in 2016, only $1.17 billion, or 10.4%, of Celgene's revenue came from outside the United States and Europe. Not all of that was from China, nor was it all derived from sales of the blockbuster trio mentioned above. Therefore, investors will need to wait to see more precise details, but for a pre-revenue company such as BeiGene, this is pretty amazing no matter the exact dollar amount. 

Celgene is looking to begin studies in solid tumors in the United States sometime in 2018. Considering that the drug candidate has exhibited safety and activity against a broad range of solid tumor types in more than 500 patients to date -- an extraordinarily high number for an early-stage asset -- BGB-A317 appears to have a better chance of reaching the market than most pipeline assets.

Meanwhile, the creative aspects of the newly formed collaboration hint at what may be the cost of doing business in China. The terms announced this week could set a high bar for other established biopharma companies looking to gain access to homegrown technology and assets in the future, although that would be good news for Chinese companies such as BeiGene trying to protect their intellectual property.

Now what

This news is definitely great for both the company's near- and long-term future. BeiGene instantly gets revenue from Chinese sales of three Celgene drugs, and it has advanced a pipeline asset closer to clinical trials in the world's biggest markets. But even so, a significant amount of the company's market cap is based on potential, which is a tricky thing to predict accurately in biopharma.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BeiGene Stock Quote
BeiGene
BGNE
$127.41 (3.59%) $4.42
Celgene Corporation Stock Quote
Celgene Corporation
CELG

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.